Atlas FDA

THORETEC HEARTMATE XVE LVAS

FDA premarket approval P920014/S017 · decided 2003-04-04

Approval details

PMA number
P920014
Supplement
S017
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
THORETEC HEARTMATE XVE LVAS
Generic name
Ventricular (assist) bypass
Applicant
Thoratec Corp
Date received
2002-11-12
Decision date
2003-04-04
Days to decision
143 days
Decision code
APPR
Product code
DSQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Pleasanton, CA
Statement
APPROVAL FOR AN EXPANDED INDICATION FOR USE FOR THE THORATEC HEARTMATE XVE LVAS. THIS DEVICE SYSTEM IS INDICATED FOR USE AS A BRIDGE TO CARDIAC TRANSPLANTATION IN CARDIAC TRANSPLANT CANDIDATES AT RISK OF IMMINENT DEATH FROM NONREVERSIBLE LEFT VENTRICULAR FAILURE. IT IS NOW ALSO INDICATED FOR USE IN PATIENTS WITH NEW YORK HEART ASSOCIATION CLASS IV END STAGE LEFT VENTRICULAR FAILURE WHO HAVE RECEIVED OPTIMAL MEDICAL THERAPY FOR AT LEAST 60 OF THE LAST 90 DAYS, AND WHO HAVE A LIFE EXPECTANCY OF LE

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
CENTRIMAG PRIMARY CONSOLE (2ND GENERATION); MAG MONITOR (K131179)Thoratec Corp2013-07-18